[Deng, Xiangping; Xie, Zhizhong; Liu, Juan; Lei, Xiaoyong; Tang, Guotao; He, Dongxiu; Peng, Junmei; Xiong, Runde; Cao, Xuan] Univ South China, Inst Pharm & Pharmacol, Hunan Prov Cooperat Innovat Ctr Mol Target New Dr, Hengyang, Peoples R China.

[Chen, Yanming] Jiuzhitang Co Ltd, Changsha, Hunan, Peoples R China.

[Tang, Guotao] U

Univ South China, Inst Pharm & Pharmacol, Hunan Prov Cooperat Innovat Ctr Mol Target New Dr, Hengyang, Peoples R China.

2 hydroxy 3 methyl n [2 (5 methyl 1h indol 3 yl)ethyl] benzamide;2 hydroxy 4 methyl n [2 (5 methyl 1h indol 3 yl)ethyl] benzamide;2 hydroxy n [2 (1h indol 3 yl)ethyl] 3 methyl benzamide;2 hydroxy n [2 (1h indol 3 yl)ethyl] 4 methyl benzamide;2 hydroxy n [2 (1h indol 3 yl)ethyl]benzamide;2 hydroxy n [2 (5 methyl 1h indol 3 yl)ethyl]benzamide;4 chloro 2 hydroxy n [2 (1h indol 3 yl)ethyl]benzamide;4 chloro 2 hydroxy n [2 (5 methyl 1h indol 3 yl)ethyl]benzamide;4 chloro n [2 (5 chloro 1h indol 3 yl)ethyl] 2 hydroxybenzamide;5 bromo 2 hydroxy n [2 (1h indol 3 yl)ethyl]benzamide;5 bromo 2 hydroxy n [2 (5 methyl 1h indol 3 yl)ethyl] benzamide;5 bromo n [2 (5 bromo 1h indol 3 yl)ethyl] 2 hydroxybenzamide;5 bromo n [2 (5 chloro 1h indol 3 yl) ethyl] 2 hydroxybenzamide;5 chloro 2 hydroxy n [2 (1h indol 3 yl)ethyl]benzamide;5 chloro 2 hydroxy n [2 (5 methyl 1h indol 3 yl)ethyl]benzamide;5 chloro n [2 (5 chloro 1h indol 3 yl)ethyl] 2 hydroxybenzamide;antineoplastic agent;hexokinase;hexokinase 2;n [2 (5 bromo 1h indol 3 yl)ethyl] 2 hydroxy 3 methyl benzamide;n [2 (5 bromo 1h indol 3 yl)ethyl] 2 hydroxy 3 methylbenzamide;n [2 (5 bromo 1h indol 3 yl)ethyl] 2 hydroxy 4 methylbenzamide;n [2 (5 bromo 1h indol 3 yl)ethyl] 2 hydroxy benzamide;n [2 (5 bromo 1h indol 3 yl)ethyl] 4 chloro 2 hydroxybenzamide;n [2 (5 bromo 1h indol 3 yl)ethyl] 5 chloro 2 hydroxybenzamide;n [2 (5 chloro 1h indol 3 yl) ethyl] 2 hydroxy 4 methylbenzamide;n [2 (5 chloro 1h indol 3 yl)ethyl] 2 hydroxy 3 methylbenzamide;n [2 (5 chloro 1h indol 3 yl)ethyl] 2 hydroxy benzamide;salicylic acid derivative;unclassified drug;A-549 cell line;antineoplastic activity;antiproliferative activity;apoptosis;Article;cancer inhibition;cell migration;concentration response;down regulation;drug design;drug determination;drug potency;drug structure;drug synthesis;drug targeting;flow cytometry;G2 phase cell cycle checkpoint;HeLa cell line;Hep-G2 cell line;in vitro study;MCF-7 cell line;priority journal;protein expression;structure activity relation;Western blotting

药学与生物科学学院